Read more
Delivered by Mario Ottiglio, Director, Public Affairs, Communications & Global Health Policy WHO Executive Board 136 – Item 9.4, 2014 Ebola virus disease outbreak Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies and national and regional industry associations across the world. In response to the...
Read moreThis IFPMA video illustrates what biotherapeutics are all about. They are typically derived from living organisms and are made by genetically engineering DNA. A high level of precision is required in the commercial manufacturing process to produce a consistent product each time. Every step we take in the production of these medicines requires highly controlled...
Read moreThe clock is ticking! In just few days, we will be joining friends and colleagues in Chinese Taipei for the Asia Regulatory Conference (4th and 5th of February). The program was crafted by a Programme Committee, which consists of regulatory professionals from regulatory authorities, industry and trade associations including the Taiwanese Food and Drug Association...
Read moreThe anti-doping and pharmaceutical communities convened in Japan today for the Second International Conference on the Pharmaceutical Industry and the Fight against Doping. The Conference, titled ‘New Developments for Clean Sport and Society, took place at Meiji-Kinen-kan in Tokyo, and followed on from the groundbreaking inaugural event in Paris in November 2012. The event was...
Read moreDelivered by Mario Ottiglio, Director, Public Affairs, Communications & Global Health Policy Check against delivery – Item 8.1, Antimicrobial Resistance Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA highly commends the WHO Secretariat...
Read moreDelivered by Mario Ottiglio, Director, Public Affairs, Communications & Global Health Policy Check against delivery – Item 5.1, Framework of engagement with non-State actors Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA welcomes...
Read moreDelivered by Laetitia Bigger, Senior Manager, Vaccines Policy Check against delivery – Item 9.3, Global Vaccine Action Plan Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA member companies are proud of their role...
Read more